CA2670300C - Improved method for the prevention of carryover contamination in nucleic acid amplification technologies - Google Patents
Improved method for the prevention of carryover contamination in nucleic acid amplification technologies Download PDFInfo
- Publication number
- CA2670300C CA2670300C CA2670300A CA2670300A CA2670300C CA 2670300 C CA2670300 C CA 2670300C CA 2670300 A CA2670300 A CA 2670300A CA 2670300 A CA2670300 A CA 2670300A CA 2670300 C CA2670300 C CA 2670300C
- Authority
- CA
- Canada
- Prior art keywords
- dna
- ung
- amplification
- abasic
- spermine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000003199 nucleic acid amplification method Methods 0.000 title claims abstract description 74
- 230000003321 amplification Effects 0.000 title claims abstract description 73
- 238000000034 method Methods 0.000 title claims abstract description 36
- 238000011109 contamination Methods 0.000 title claims abstract description 26
- 150000007523 nucleic acids Chemical class 0.000 title claims description 26
- 108020004707 nucleic acids Proteins 0.000 title claims description 24
- 102000039446 nucleic acids Human genes 0.000 title claims description 24
- 238000005516 engineering process Methods 0.000 title description 3
- 230000002265 prevention Effects 0.000 title description 3
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 claims abstract description 82
- 229920000768 polyamine Polymers 0.000 claims abstract description 41
- 229940063675 spermine Drugs 0.000 claims abstract description 41
- 102000004190 Enzymes Human genes 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 22
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 claims abstract description 14
- 108020001738 DNA Glycosylase Proteins 0.000 claims abstract description 11
- 102000028381 DNA glycosylase Human genes 0.000 claims abstract description 11
- 229940063673 spermidine Drugs 0.000 claims abstract description 7
- 208000035657 Abasia Diseases 0.000 claims description 52
- 238000003752 polymerase chain reaction Methods 0.000 claims description 30
- 230000015556 catabolic process Effects 0.000 claims description 21
- 238000006731 degradation reaction Methods 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 239000000138 intercalating agent Substances 0.000 claims description 6
- XFNJVJPLKCPIBV-UHFFFAOYSA-N trimethylenediamine Chemical compound NCCCN XFNJVJPLKCPIBV-UHFFFAOYSA-N 0.000 claims description 4
- 239000012488 sample solution Substances 0.000 claims description 3
- VILCJCGEZXAXTO-UHFFFAOYSA-N 2,2,2-tetramine Chemical compound NCCNCCNCCN VILCJCGEZXAXTO-UHFFFAOYSA-N 0.000 claims 1
- 229960001124 trientine Drugs 0.000 claims 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract description 38
- 238000006243 chemical reaction Methods 0.000 abstract description 28
- 229940035893 uracil Drugs 0.000 abstract description 19
- 102000010719 DNA-(Apurinic or Apyrimidinic Site) Lyase Human genes 0.000 abstract description 4
- 108010063362 DNA-(Apurinic or Apyrimidinic Site) Lyase Proteins 0.000 abstract description 4
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 108020004414 DNA Proteins 0.000 description 53
- 108091093088 Amplicon Proteins 0.000 description 32
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 19
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 14
- 102100037111 Uracil-DNA glycosylase Human genes 0.000 description 12
- 238000002203 pretreatment Methods 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 108010072685 Uracil-DNA Glycosidase Proteins 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000000356 contaminant Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000003757 reverse transcription PCR Methods 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 125000003277 amino group Chemical group 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000013615 primer Substances 0.000 description 7
- -1 thrimethylenediamine Chemical compound 0.000 description 7
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 6
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 6
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 6
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 6
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000002777 nucleoside Substances 0.000 description 6
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 6
- 239000001226 triphosphate Substances 0.000 description 6
- 235000011178 triphosphate Nutrition 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 238000000137 annealing Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000009830 intercalation Methods 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000012408 PCR amplification Methods 0.000 description 4
- 238000002944 PCR assay Methods 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 3
- 239000007997 Tricine buffer Substances 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 3
- 230000007515 enzymatic degradation Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 229940071125 manganese acetate Drugs 0.000 description 3
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 3
- 235000011056 potassium acetate Nutrition 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- MXHRCPNRJAMMIM-SHYZEUOFSA-N 2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-SHYZEUOFSA-N 0.000 description 2
- JTBBWRKSUYCPFY-UHFFFAOYSA-N 2,3-dihydro-1h-pyrimidin-4-one Chemical compound O=C1NCNC=C1 JTBBWRKSUYCPFY-UHFFFAOYSA-N 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 2
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 2
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 230000033616 DNA repair Effects 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 101000807668 Homo sapiens Uracil-DNA glycosylase Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 2
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 102000006943 Uracil-DNA Glycosidase Human genes 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- MXHRCPNRJAMMIM-UHFFFAOYSA-N desoxyuridine Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-UHFFFAOYSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000005382 thermal cycling Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- 108010036364 Deoxyribonuclease IV (Phage T4-Induced) Proteins 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
- 101000615492 Homo sapiens Methyl-CpG-binding domain protein 4 Proteins 0.000 description 1
- 101000664956 Homo sapiens Single-strand selective monofunctional uracil DNA glycosylase Proteins 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000005700 Putrescine Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 102100038661 Single-strand selective monofunctional uracil DNA glycosylase Human genes 0.000 description 1
- 101710160987 Uracil-DNA glycosylase Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 102000052894 human MBD4 Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229920000412 polyarylene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- GUKSGXOLJNWRLZ-UHFFFAOYSA-N thymine glycol Chemical compound CC1(O)C(O)NC(=O)NC1=O GUKSGXOLJNWRLZ-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7611108P | 2008-06-26 | 2008-06-26 | |
| US61/076,111 | 2008-06-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2670300A1 CA2670300A1 (en) | 2009-12-26 |
| CA2670300C true CA2670300C (en) | 2014-12-09 |
Family
ID=41136785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2670300A Expired - Fee Related CA2670300C (en) | 2008-06-26 | 2009-06-25 | Improved method for the prevention of carryover contamination in nucleic acid amplification technologies |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8669061B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2138590B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5596308B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101613730B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2670300C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2386023T3 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8669061B2 (en) | 2008-06-26 | 2014-03-11 | Roche Molecular Systems, Inc. | Method for the prevention of carryover contamination in nucleic acid amplification technologies |
| US20150024398A1 (en) * | 2011-08-05 | 2015-01-22 | Ibis Biosciences, Inc. | Analysis of genetic biomarkers for forensic analysis and fingerprinting |
| ES2449665B2 (es) * | 2012-09-19 | 2014-07-17 | Servizo Galego De Saúde-Conselleria De Sanidade, Xunta De Galicia | Procedimiento para el diagnóstico clínico de una enfermedad infecciosa basada en el empleo de la PCR cuantitativa, oligonucleótidos marcados de 8 a 9 nucleótidos de longitud y la UNG del Bacalao del Atlántico (Gadus morhua). |
| CA2930942A1 (en) * | 2013-11-18 | 2015-05-21 | Rubicon Genomics, Inc. | Degradable adaptors for background reduction |
| US10036061B2 (en) | 2013-12-20 | 2018-07-31 | Roche Molecular Systems, Inc. | Oligonucleotide inhibitor of DNA polymerases |
| US10323273B2 (en) | 2014-06-05 | 2019-06-18 | Qiagen Gmbh | Optimization of DNA amplification reactions |
| ES2904909T3 (es) | 2014-10-08 | 2022-04-06 | Univ Cornell | Método para la identificación y la cuantificación relativa de cambios en la expresión de secuencias de ácidos nucleicos, en variantes de corte y empalme, en la translocación, en el número de copias o en la metilación utilizando reacciones combinadas de nucleasa, de ligadura y de polimerasa con prevención de arrastre |
| CN104389026A (zh) * | 2014-10-30 | 2015-03-04 | 北京诺禾致源生物信息科技有限公司 | 单细胞转录组测序文库的构建方法及其应用 |
| WO2017043114A1 (ja) * | 2015-09-07 | 2017-03-16 | 株式会社ファスマック | 等温増幅反応産物の多項目同時検出方法 |
| EP3485038B1 (en) | 2016-07-12 | 2020-12-23 | H. Hoffnabb-La Roche Ag | Primer extension target enrichment |
| ES2875318T3 (es) | 2016-07-18 | 2021-11-10 | Hoffmann La Roche | Procedimiento para generar colecciones de ADN circular monocatenario para secuenciación de molécula única |
| JP2021506314A (ja) | 2017-12-21 | 2021-02-22 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 単一方向デュアルプローブプライマー伸長による標的濃縮 |
| US20220251580A1 (en) * | 2019-05-07 | 2022-08-11 | Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences | Improved gene editing system |
| EP4031679A1 (en) | 2019-09-20 | 2022-07-27 | F. Hoffmann-La Roche AG | Immune repertoire profiling by primer extension target enrichment |
| US20230287508A1 (en) | 2020-06-08 | 2023-09-14 | Roche Sequencing Solutions, Inc. | Methods and compositions for detecting structural rearrangements in a genome |
| CN113186037B (zh) * | 2021-04-23 | 2022-12-13 | 山东博弘基因科技有限公司 | 一种核酸清除剂 |
| JP2024538122A (ja) * | 2021-10-15 | 2024-10-18 | キアゲン サイエンシーズ リミテッド ライアビリティ カンパニー | Ｄｎａライブラリを作製するための方法およびその使用 |
| CN114214395A (zh) * | 2021-12-31 | 2022-03-22 | 上海星耀医学科技发展有限公司 | 一种提高基因检测准确性的核酸扩增方法与试剂盒 |
| CN119546776A (zh) | 2022-07-14 | 2025-02-28 | 豪夫迈·罗氏有限公司 | 通过单向双重探针引物延伸进行的变异等位基因富集 |
| CN116773291B (zh) * | 2023-03-31 | 2024-04-19 | 艾普拜生物科技(苏州)有限公司 | 一种石蜡切片dna预处理试剂及方法 |
| WO2024222446A1 (zh) * | 2023-04-23 | 2024-10-31 | 南京诺唯赞生物科技股份有限公司 | 一种去除非目标核酸模板的方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH089997B2 (ja) | 1987-05-26 | 1996-01-31 | 日立冷熱株式会社 | 多翼送風機 |
| US5683896A (en) | 1989-06-01 | 1997-11-04 | Life Technologies, Inc. | Process for controlling contamination of nucleic acid amplification reactions |
| ATE176002T1 (de) * | 1990-07-24 | 1999-02-15 | Hoffmann La Roche | Verringerung von nicht spezifischer amplifikation während einer (in vitro) nukleinsäure amplifikation unter verwendung von modifizierten nukleinsäure basen |
| CA2073298C (en) * | 1991-07-12 | 2007-04-17 | James L. Hartley | Process for controlling contamination of nucleic acid amplification reactions |
| JP3416981B2 (ja) | 1993-03-30 | 2003-06-16 | 株式会社島津製作所 | 核酸合成法 |
| JPH089997A (ja) | 1994-06-28 | 1996-01-16 | Shimadzu Corp | 核酸合成法およびそれに用いる試薬キット |
| US6413747B1 (en) | 1994-10-03 | 2002-07-02 | Shimadzu Corporation | Enhancement of nucleic acid amplification by the addition of a polyamine |
| US6190865B1 (en) * | 1995-09-27 | 2001-02-20 | Epicentre Technologies Corporation | Method for characterizing nucleic acid molecules |
| DE19545320A1 (de) | 1995-12-05 | 1997-06-12 | Boehringer Mannheim Gmbh | Thermolabile Uracil-DNA-Glykosylase, Verfahren zu deren Herstellung und Verwendung zur Entfernung von Uracil aus DNA |
| GB9600384D0 (en) | 1996-01-09 | 1996-03-13 | Nyfotek As | Dna glycosylases |
| JP4629167B2 (ja) | 1997-10-17 | 2011-02-09 | 株式会社島津製作所 | 核酸合成法 |
| EP1041159A3 (de) | 1999-03-26 | 2000-10-25 | MIRA Diagnostika GmbH | Verfahren, Oligonucleotide zum Abbau von in-vitro synthetisierten Nucleinsäuremolekülen |
| EP1038974A1 (de) | 1999-03-26 | 2000-09-27 | Mira Diagnostica GmbH | Verfahren, Oligonucleotide zum Abbau von in-vitro synthetisierten Nucleinsäuremolekülen |
| JP2001008680A (ja) | 1999-06-30 | 2001-01-16 | Shimadzu Corp | 核酸合成法 |
| US20040152094A1 (en) | 2001-05-10 | 2004-08-05 | Steffen Danielsen | Method for producing recombined polynucleotides |
| EP2038429B1 (en) * | 2006-06-30 | 2013-08-21 | Nugen Technologies, Inc. | Methods for fragmentation and labeling of nucleic acids |
| US8669061B2 (en) | 2008-06-26 | 2014-03-11 | Roche Molecular Systems, Inc. | Method for the prevention of carryover contamination in nucleic acid amplification technologies |
-
2009
- 2009-06-16 US US12/485,569 patent/US8669061B2/en active Active
- 2009-06-24 EP EP09008229A patent/EP2138590B1/en active Active
- 2009-06-24 ES ES09008229T patent/ES2386023T3/es active Active
- 2009-06-25 CA CA2670300A patent/CA2670300C/en not_active Expired - Fee Related
- 2009-06-25 JP JP2009151195A patent/JP5596308B2/ja active Active
- 2009-06-26 CN CN200910146289.7A patent/CN101613730B/zh active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010004884A (ja) | 2010-01-14 |
| EP2138590A1 (en) | 2009-12-30 |
| HK1138330A1 (en) | 2010-08-20 |
| EP2138590B1 (en) | 2012-05-30 |
| US8669061B2 (en) | 2014-03-11 |
| CN101613730B (zh) | 2014-06-04 |
| JP5596308B2 (ja) | 2014-09-24 |
| CN101613730A (zh) | 2009-12-30 |
| US20100093041A1 (en) | 2010-04-15 |
| CA2670300A1 (en) | 2009-12-26 |
| ES2386023T3 (es) | 2012-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2670300C (en) | Improved method for the prevention of carryover contamination in nucleic acid amplification technologies | |
| US12180539B2 (en) | Application of CAS protein, method for detecting target nucleic acid molecule and kit | |
| US11584955B2 (en) | Application of Cas protein, method for detecting target nucleic acid molecule and kit | |
| JP2022008577A (ja) | 限られたヌクレオチド組成を有するプライマーを用いた増幅 | |
| US11268116B2 (en) | Endonuclase-assisted isothermal amplification using contamination-free reagents | |
| US8361712B2 (en) | Contamination-free reagents for nucleic acid amplification | |
| US20160130673A1 (en) | Nucleic acid detection by oligonucleotide probes cleaved by both exonuclease and endonuclease | |
| CN100379861C (zh) | 核酸扩增或检测用试剂的稳定化方法和保存方法 | |
| EP3033431B1 (en) | Endonuclease-assisted isothermal amplification using contamination-free reagents | |
| JP5816094B2 (ja) | 核酸の増幅のおよび／または検出の方法、キット及びこの方法の使用 | |
| US10358673B2 (en) | Method of amplifying nucleic acid sequences | |
| WO2021221109A1 (ja) | Ｒｎａウイルスの検出方法 | |
| US9637780B2 (en) | Controlled inhibition and re-activation of DNA polymerases by cleavable oligonucleotide inhibitors | |
| HK1138330B (en) | Improved method for the prevention of carryover contamination in nucleic acid amplification technologies | |
| WO2006047461A1 (en) | Repair of nucleic acids for improved amplification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20140408 |
|
| MKLA | Lapsed |
Effective date: 20190625 |